首页>投融资
Halda
B轮
Halda Therapeutics是一家研究阶段药物发现公司。该公司的抗癌策略与众不同，并不靶向与癌症发生和进展相关的驱动因子，有望克服多种癌症耐药机制，为难治性患者带来新的治疗选择。Halda的在研疗法称为调节诱导接近靶向嵌合体（RIPTAC）。它的一端可以与肿瘤细胞中高度表达的蛋白相结合，而另一端与细胞内和细胞生存紧密相关的蛋白结合。它们构成的三元复合体会抑制维持细胞生存蛋白的功能，从而导致肿瘤细胞的死亡。
基本信息
-
公司全称Halda Therapeutics LLC
-
类型抗癌药物开发商
-
产业领域药品研发/制造
-
公司人数15~50人
-
地址New Haven
-
联系电话475-210-0212
-
邮箱info@haldathera.com
-
成立时间2018-01-01
投融资
-
2024-08-12B轮1.26亿美元Deep Track CapitalFrazier ManagementRA CapitalVida VenturesBoxer CapitalTaiho VenturesCanaan PartnersAccess IndustriesElm Street VenturesCT Innovations
-
2023-02-15未透露7600万美元未透露
相关投融资企业
收并购
Ipsen SA formerly the Beaufour-Ipsen Group, is a European pharmaceutical group founded in 1929. The group's research and development is targeted to the disease areas of endocrinology, oncology and neuromuscular disorders.In April 2011, Ipsen SA was nearing to completing a strategic review and planned to announce details in June of that year. In June 2011, the company announced restructuring plans in which it would restructure its business into four market-based franchises and focus its R&D on its peptide and tocin-based technologies. The company also planned to merge its R&D departments and close its Barcelona, Spain R&D center.The company planned to create four franchises: Endocrinology/Somatuline (lanreotide depot); Neurology/Dysport (abobotulinumtoxinA); Uro-oncology/Decapeptyl (triptorelin pamoate); and Hemophilia. It also planned to maximize the value of its short stature business, and this was to be managed directly by regions and countries. Ipsen also intended to to grow its primary care
战略投资
丹望医疗科技上海有限公司位于上海南翔精准医学产业园，致力于将最新的再生医学类器官技术临床转化，应用于疾病的诊疗、新药筛选、肿瘤标志物开发与鉴定，努力为临床提供个性化治疗的新技术，为新药研发提供精准、高效、优质的类器官模型。公司拥有全球领先的类器官技术创新平台，已建立了肺、胰腺、乳腺、胃、肠、肝等多个人体器官组织的类器官培养体系。
A轮
Ottimo Pharma是一家私营生物技术公司，由Medicxi和Jonny Finlay于2020年共同创立，专注于开发用于实体瘤的开创性创新癌症疗法。该公司的主导项目Jankistomig是一种PD1-VEGFR2双功能抗体，旨在通过单一IgG疗法同时靶向免疫检查点抑制和血管生成。通过推进这种双途径方法，Ottimo Pharma旨在改善癌症治疗结果，降低总体医疗负担。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息